{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine",
                    "control": "5-fluorouracil",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[5.7, 4.2, 18, 2, 1996]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control]",
                "outcomes": "['5.7', '4.2']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine",
                    "control": "5-fluorouracil",
                    "phase": "3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "more favorable than 5-fluorouracil"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine",
                    "Control": "5-fluorouracil",
                    "Phase": "3",
                    "Side Effects": "more favorable than 5-fluorouracil",
                    "FDA Approval": "1996",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['18%', '2%']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[6.4, 6, 24, 19, 2005]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "less favorable than gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "less favorable than gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['24%', '19%']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[8.5, 6.7, 35, 22, 2013]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval year]",
                "outcomes": "[8.5, 6.7, 35, 22, 2013]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['8.5', '6.7']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "less favorable than gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "control": "gemcitabine",
                    "phase": "3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "less favorable than gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2013",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['35%', '22%']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                "outcomes": "[11.1, 6.8, 48.4, 20.6, n/a]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                "outcomes": "[11.1, 6.8, 48.4, 20.6, n/a]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['11.1', '6.8']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "less favorable than gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "control": "gemcitabine",
                    "phase": "2/3",
                    "cancer type": "pancreatic cancer",
                    "side effects": "less favorable than gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "FOLFIRINOX",
                    "Control": "gemcitabine",
                    "Phase": "2/3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['48.4%', '20.6%']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "components": "oxaliplatin, irinotecan, fluorouracil, leucovorin"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "components": "oxaliplatin, irinotecan, fluorouracil, leucovorin"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "FOLFIRINOX",
                    "components": "oxaliplatin, irinotecan, fluorouracil, leucovorin"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                "outcomes": "[10, 5, 36, 18, n/a]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "cancer type": "pancreatic cancer"
                },
                "measures": "[median survival (months), median survival control (months), one-year survival (%), one-year survival control (%), FDA approval]",
                "outcomes": "[10, 5, 36, 18, n/a]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['10', '5']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "cancer type": "pancreatic cancer",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "cell encapsulation + ifosfamide",
                    "control": "5-fluorouracil",
                    "phase": "2",
                    "cancer type": "pancreatic cancer",
                    "side effects": "more favorable than 5-fluorouracil or gemcitabine"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "cell encapsulation + ifosfamide",
                    "Control": "5-fluorouracil",
                    "Phase": "2",
                    "Side Effects": "more favorable than 5-fluorouracil or gemcitabine",
                    "FDA Approval": "n/a",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['One-Year Survival Therapy', 'One-Year Survival Control']",
                "outcomes": "['36%', '18%']"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "treatment": "cell encapsulation + ifosfamide",
                    "dose": "2 g/m2",
                    "toxicity": "Grade 3 or Grade 4 NCI toxicities",
                    "patients affected": "five",
                    "median survival": "9.5 months"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                    "Control": "gemcitabine",
                    "Phase": "3",
                    "Side Effects": "less favorable than gemcitabine",
                    "FDA Approval": "2005",
                    "Cancer Type": "pancreatic cancer"
                },
                "measures": "['Median Survival Therapy', 'Median Survival Control']",
                "outcomes": "['6.4', '6']"
            },
            "match": "no"
        }
    ],
    "total_extracted_claims": 12,
    "total_ground_truth_claims": 10,
    "number_of_matches": 9
}